Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;13(2):PCC.10l01039blu.
doi: 10.4088/PCC.10l01039blu.

Venlafaxine for the treatment of hormonal therapy-induced hot flashes in a male patient

Harmit Singh  1 , Ashish Sharma
Affiliations

Venlafaxine for the treatment of hormonal therapy-induced hot flashes in a male patient

Harmit Singh et al. Prim Care Companion CNS Disord. 2011.
No abstract available

PubMed Disclaimer

References

    1. Schow DA, Renfer LG, Rozanski TA, et al. Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J. 1998;91(9):855–857. - PubMed
    1. Karling P, Hammar M, Varenhorst E. Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol. 1994;152(4):1170–1173. - PubMed
    1. Alekshun TJ, Patterson SG. Management of hot flashes in men with prostate cancer being treated with androgen deprivation therapy. Support Cancer Ther. 2006;4(1):30–37. - PubMed
    1. Irani J, Salomon L, Oba R, et al. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol. 2010;11(2):147–154. - PubMed
    1. Quella SK, Loprinzi CL, Sloan J, et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol. 1999;162(1):98–102. - PubMed